Role of fulvestrant in the treatment of postmenopausal metastatic breast cancer patients

Francesca Poggio, Matteo Lambertini, Eva Blondeaux, Marina Vaglica, Alessia Levaggi, Paolo Pronzato, Lucia Del Mastro

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Introduction: Endocrine therapy is considered the cornerstone treatment for postmenopausal women with hormone-receptor positive metastatic breast cancer. Fulvestrant is a selective estrogen receptor down-regulator (SERD) with demonstrated activity and efficacy in the treatment of these patients. Areas covered: The present manuscript aims to review the mechanism of action of fulvestrant, the clinical efficacy data with the use of different dosages and schedules, and finally its role in association with other medications. Expert commentary: Fulvestrant is an active compound with an excellent safety profile for the treatment of women with hormone receptor-positive metastatic breast cancer, The combination of fulvestrant with targeted agents showed increased efficacy and is expected to become a new standard treatment. Results of two clinical trials (i.e. the FALCON and FEVEX trials) are awaited to better clarify the place of fulvestrant in the armamentarium of the available therapies for the treatment of hormone receptor-positive metastatic breast cancer.

Original languageEnglish
Pages (from-to)1153-1161
Number of pages9
JournalExpert Review of Clinical Pharmacology
Volume9
Issue number9
DOIs
Publication statusPublished - Sep 1 2016

Fingerprint

Breast Neoplasms
Hormones
Therapeutics
Manuscripts
Estrogen Receptors
fulvestrant
Appointments and Schedules
Clinical Trials
Safety

Keywords

  • endocrine resistance
  • endocrine therapy
  • Fulvestrant
  • metastatic breast cancer
  • selective estrogen receptor downregulator (SERD)

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Role of fulvestrant in the treatment of postmenopausal metastatic breast cancer patients. / Poggio, Francesca; Lambertini, Matteo; Blondeaux, Eva; Vaglica, Marina; Levaggi, Alessia; Pronzato, Paolo; Del Mastro, Lucia.

In: Expert Review of Clinical Pharmacology, Vol. 9, No. 9, 01.09.2016, p. 1153-1161.

Research output: Contribution to journalArticle

Poggio, Francesca ; Lambertini, Matteo ; Blondeaux, Eva ; Vaglica, Marina ; Levaggi, Alessia ; Pronzato, Paolo ; Del Mastro, Lucia. / Role of fulvestrant in the treatment of postmenopausal metastatic breast cancer patients. In: Expert Review of Clinical Pharmacology. 2016 ; Vol. 9, No. 9. pp. 1153-1161.
@article{50cfde0be34a454786537857f381d222,
title = "Role of fulvestrant in the treatment of postmenopausal metastatic breast cancer patients",
abstract = "Introduction: Endocrine therapy is considered the cornerstone treatment for postmenopausal women with hormone-receptor positive metastatic breast cancer. Fulvestrant is a selective estrogen receptor down-regulator (SERD) with demonstrated activity and efficacy in the treatment of these patients. Areas covered: The present manuscript aims to review the mechanism of action of fulvestrant, the clinical efficacy data with the use of different dosages and schedules, and finally its role in association with other medications. Expert commentary: Fulvestrant is an active compound with an excellent safety profile for the treatment of women with hormone receptor-positive metastatic breast cancer, The combination of fulvestrant with targeted agents showed increased efficacy and is expected to become a new standard treatment. Results of two clinical trials (i.e. the FALCON and FEVEX trials) are awaited to better clarify the place of fulvestrant in the armamentarium of the available therapies for the treatment of hormone receptor-positive metastatic breast cancer.",
keywords = "endocrine resistance, endocrine therapy, Fulvestrant, metastatic breast cancer, selective estrogen receptor downregulator (SERD)",
author = "Francesca Poggio and Matteo Lambertini and Eva Blondeaux and Marina Vaglica and Alessia Levaggi and Paolo Pronzato and {Del Mastro}, Lucia",
year = "2016",
month = "9",
day = "1",
doi = "10.1080/17512433.2016.1215243",
language = "English",
volume = "9",
pages = "1153--1161",
journal = "Expert Review of Clinical Pharmacology",
issn = "1751-2433",
publisher = "ROUTLEDGE JOURNALS, TAYLOR FRANCIS LTD",
number = "9",

}

TY - JOUR

T1 - Role of fulvestrant in the treatment of postmenopausal metastatic breast cancer patients

AU - Poggio, Francesca

AU - Lambertini, Matteo

AU - Blondeaux, Eva

AU - Vaglica, Marina

AU - Levaggi, Alessia

AU - Pronzato, Paolo

AU - Del Mastro, Lucia

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Introduction: Endocrine therapy is considered the cornerstone treatment for postmenopausal women with hormone-receptor positive metastatic breast cancer. Fulvestrant is a selective estrogen receptor down-regulator (SERD) with demonstrated activity and efficacy in the treatment of these patients. Areas covered: The present manuscript aims to review the mechanism of action of fulvestrant, the clinical efficacy data with the use of different dosages and schedules, and finally its role in association with other medications. Expert commentary: Fulvestrant is an active compound with an excellent safety profile for the treatment of women with hormone receptor-positive metastatic breast cancer, The combination of fulvestrant with targeted agents showed increased efficacy and is expected to become a new standard treatment. Results of two clinical trials (i.e. the FALCON and FEVEX trials) are awaited to better clarify the place of fulvestrant in the armamentarium of the available therapies for the treatment of hormone receptor-positive metastatic breast cancer.

AB - Introduction: Endocrine therapy is considered the cornerstone treatment for postmenopausal women with hormone-receptor positive metastatic breast cancer. Fulvestrant is a selective estrogen receptor down-regulator (SERD) with demonstrated activity and efficacy in the treatment of these patients. Areas covered: The present manuscript aims to review the mechanism of action of fulvestrant, the clinical efficacy data with the use of different dosages and schedules, and finally its role in association with other medications. Expert commentary: Fulvestrant is an active compound with an excellent safety profile for the treatment of women with hormone receptor-positive metastatic breast cancer, The combination of fulvestrant with targeted agents showed increased efficacy and is expected to become a new standard treatment. Results of two clinical trials (i.e. the FALCON and FEVEX trials) are awaited to better clarify the place of fulvestrant in the armamentarium of the available therapies for the treatment of hormone receptor-positive metastatic breast cancer.

KW - endocrine resistance

KW - endocrine therapy

KW - Fulvestrant

KW - metastatic breast cancer

KW - selective estrogen receptor downregulator (SERD)

UR - http://www.scopus.com/inward/record.url?scp=84981743435&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84981743435&partnerID=8YFLogxK

U2 - 10.1080/17512433.2016.1215243

DO - 10.1080/17512433.2016.1215243

M3 - Article

AN - SCOPUS:84981743435

VL - 9

SP - 1153

EP - 1161

JO - Expert Review of Clinical Pharmacology

JF - Expert Review of Clinical Pharmacology

SN - 1751-2433

IS - 9

ER -